Forecast of the antidyslipidemic markets in the US, Japan, France, Germany, Italy, Spain, and the UK. Volume and revenue sales forecast to 2019.
In-depth review of the cardiovascular and metabolic markets, including analysis and comparison of key sales trends in the therapy areas of diabetes, dyslipidemia, hypertension and thrombosis over the forecast (2010–19) period.
In the wake of Lipitor’s patent expiry, the dyslipidemia market continues to face increasing genericization leading to falling sales in key drug classes.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions